Who Exports Plasma from India — 215 Suppliers Behind a $2.8M Market

Hyderabad, often referred to as the "Bulk Drug Capital of India," is renowned for its extensive production of active pharmaceutical ingredients (APIs) and biologics. A notable facility in this region is operated by Ichor Biologics, which runs a state-of-the-art cGMP/WHO-GMP-approved plasma fractionation plant in Genome Valley. This facility spans over 100,000 square feet and is the first in India to implement a fully integrated, chromatography-based plasma fractionation process. Ichor manufactures critical plasma-derived products such as Human Normal Immunoglobulin (IVIG), Human Serum Albumin, and Human Coagulation Factors, supplying both domestic and international markets.

The Ahmedabad-Vadodara corridor in Gujarat is a prominent hub for pharmaceutical formulations. While specific data on plasma product manufacturing in this region is limited, the area's robust infrastructure and skilled workforce make it a potential site for future investments in plasma-derived therapeutics.

The Mumbai-Thane-Raigad belt serves as a critical export gateway for pharmaceutical products. Companies like Albert David Ltd., a leading exporter of plasma products, leverage the proximity to major ports and international airports to facilitate efficient global distribution. This strategic location enhances the competitiveness of firms involved in the export of plasma-derived products.

The Baddi-Nalagarh region in Himachal Pradesh has emerged as a significant pharmaceutical manufacturing zone, primarily due to favorable tax incentives. While the focus has traditionally been on generic formulations, the region's supportive policies and infrastructure present opportunities for diversification into plasma product manufacturing.

• Evaluate Supplier Capabilities: Assess the technological advancements and production capacities of suppliers, such as Ichor Biologics in Hyderabad, to ensure they meet quality and regulatory standards.

• Leverage Export Infrastructure: Utilize the logistical advantages offered by clusters like Mumbai-Thane-Raigad for efficient international distribution of plasma products.

• Monitor Emerging Hubs: Stay informed about developments in regions like Ahmedabad-Vadodara and Baddi-Nalagarh, which may offer new opportunities for sourcing plasma-derived therapeutics.

• Ensure Regulatory Compliance: Verify that suppliers adhere to international regulatory standards, including approvals from agencies such as the FDA, EMA, WHO, CDSCO, and NPPA, to maintain product quality and market access.

By strategically engaging with these pharmaceutical clusters and adhering to regulatory requirements, TransData Nexus can optimize its supply chain for plasma-derived products.